FARMINGDALE, N.Y. - December 5, 2018 - Precision Label Corporation, a New York-based converter serving major cosmetic brands, is expanding its digital production capabilities with the addition of ...
DURHAM – Precision Biosciences has inked a deal with gene editing company iECURE to advance one of Precision’s drug candidates into Phase 1 clinical studies. The agreement also gives iECURE a license ...
Precision BioSciences, Inc. DTIL announced that it has entered into an exclusive license agreement with New York-based Tiziana Life Sciences plc TLSA to develop the latter’s fully human anti-CD3 ...
As fellow gene editing firm Crispr Therapeutics AG hosted an innovation day in which it confirmed plans for regulatory filings by year-end for an ex vivo gene editing therapy in sickle cell disease ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Precision BioSciences continues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results